Grant: DRA: Canada Impact+ Research Training Awards - Doctoral
University of Ottawa
$120,000.00
Development of Novel Antisense Oligonucleotide Therapies Targeting Aberrant Splicing to Overcome Cancer Treatment Resistance
EF 2025-26
Résumé
"I propose to develop a new class of antisense oligonucleotide (ASO) therapies designed to precisely correct
cancer-specific splicing defects, thereby addressing the challenge of treatment resistance. Cancer pathogenesis is
driven not only by genetic mutations but also by profound dysregulation in post-transcriptional gene processing.
Alternative splicing is a central regulatory node in this process, and its widespread dysregulation in cancer leads to the
production of oncogenic protein isoforms, enhanced tumor heterogeneity, and therapy resistance. Despite its critical
role, therapeutic strategies to directly target and correct oncogenic splicing errors remain largely underdeveloped.
I will employ an interdisciplinary strategy. First, I will employ bioinformatics and long-read sequencing to systematically
map and identify functionally critical aberrant splicing events in treatment-resistant cancers (e.g., endocrine
therapy-resistant breast cancer). Subsequently, I will rationally design and chemically synthesize a panel of
splice-switching ASOs targeting these specific splicing junctions or regulatory elements. ASOs are short, synthetic
nucleic acids that can bind with high affinity and specificity to target pre-mRNA via Watson-Crick base pairing, thereby
precisely interfering with spliceosome assembly to ""reprogram"" erroneous splicing patterns back to normal. We will
then validate the efficacy of these ASOs in cell lines and patient-derived organoid models, assessing their ability to
correct splicing patterns, inhibit downstream oncogenic signaling, and reverse malignant phenotypes. Finally, I will
evaluate the in vivo anti-tumor activity, pharmacokinetics, and safety profile of lead ASO candidates in preclinical
models such as patient-derived xenografts (PDX)."
Programme
DRA: Canada Impact+ Research Training Awards - Doctoral
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
568209
Name
Zhang Liwen
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Canada Impact+ Research Training Awards - Doctoral
Projecttitle
Development of Novel Antisense Oligonucleotide Therapies Targeting Aberrant Splicing to Overcome Cancer Treatment Resistance
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA: Canada Impact+ Research Training Awards - Doctoral
Keyworddelim
Alternative Splicing; Antisense Oligonucleotides (Asos); Cancer Therapeutics; Splicing Factors; Therapy Resistance
Abstract
"I propose to develop a new class of antisense oligonucleotide (ASO) therapies designed to precisely correct
cancer-specific splicing defects, thereby addressing the challenge of treatment resistance. Cancer pathogenesis is
driven not only by genetic mutations but also by profound dysregulation in post-transcriptional gene processing.
Alternative splicing is a central regulatory node in this process, and its widespread dysregulation in cancer leads to the
production of oncogenic protein isoforms, enhanced tumor heterogeneity, and therapy resistance. Despite its critical
role, therapeutic strategies to directly target and correct oncogenic splicing errors remain largely underdeveloped.
I will employ an interdisciplinary strategy. First, I will employ bioinformatics and long-read sequencing to systematically
map and identify functionally critical aberrant splicing events in treatment-resistant cancers (e.g., endocrine
therapy-resistant breast cancer). Subsequently, I will rationally design and chemically synthesize a panel of
splice-switching ASOs targeting these specific splicing junctions or regulatory elements. ASOs are short, synthetic
nucleic acids that can bind with high affinity and specificity to target pre-mRNA via Watson-Crick base pairing, thereby
precisely interfering with spliceosome assembly to ""reprogram"" erroneous splicing patterns back to normal. We will
then validate the efficacy of these ASOs in cell lines and patient-derived organoid models, assessing their ability to
correct splicing patterns, inhibit downstream oncogenic signaling, and reverse malignant phenotypes. Finally, I will
evaluate the in vivo anti-tumor activity, pharmacokinetics, and safety profile of lead ASO candidates in preclinical
models such as patient-derived xenografts (PDX)."
Competitiondate
202603
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Zhang, Liwen
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~